We investigate whether A1C1 and A1Br are promising candidates for laser cooling. We report new ab initio calculations on the ground state X1E＋ and two low-lying states （A1H and a3H） of A1C1 and A1Br. The calculated...We investigate whether A1C1 and A1Br are promising candidates for laser cooling. We report new ab initio calculations on the ground state X1E＋ and two low-lying states （A1H and a3H） of A1C1 and A1Br. The calculated spectroscopic constants show good agreement with available theoretical and experimental results. We also obtain the permanent dipole moments （PDMs） curve at multi-reference configuration interaction （MRCI） level of theory. The transition properties of A1H and a3H states are predicted, including the transition dipole moments （TDMs）, Franck-Condon factors （FCFs）, radiative times and radiative width. The calculated radiative lifetimes are of the order of a nanosecond, implying that they are sufficiently short for rapid laser cooling. Both A1C1 and A1Br have highly diagonally distributed FCFs which are crucial requirement for molecular laser cooling. The results demonstrate the feasibility of laser cooling A1C1 and A1Br, and we propose laser cooling schemes for A1C1 and A1Br.展开更多
<div style="text-align:justify;"> <span style="font-family:Verdana;">Type 2 diabetes mellitus is a growing health problem, characterized by insulin resistance progressing to beta cell d...<div style="text-align:justify;"> <span style="font-family:Verdana;">Type 2 diabetes mellitus is a growing health problem, characterized by insulin resistance progressing to beta cell dysfunction and insulin deficiency, most of these patients will need intensification of treatment and initiation of insulin to delay or prevent diabetic complications. Glycemic control is the most important aspect of management, and in reducing morbidity and mortality of the diseases. Control of plasma glucose in patients with diabetes can be assessed by HbA1c, FPG, PPG, but still HbA1c% remains the gold standard for assessment of glycemic control and follow up of diabetic patients. The aim of this study is to assess HbA1c% in patients on oral anti-diabetic drugs, with poor glycemic control before and after adding basal insulin, with titration of the dose of insulin depending on fasting blood sugar. 82 patients with uncontrolled type 2 diabetes (43.9% male, 56.1% female), with HbA1c more than 9%, on two types of oral diabetic medication or more, were started on basal insulin (glargine, lantus) and followed for three to six months. Overall 82 patients with type 2 diabetes mellitus were included in the study. The mean age of the study population was 58.4 years, the mean duration of the disease range was 13.4 years. All patients with HbA1c more than 9%, without organ failure, were included in the study. The mean HbA1c overall had decreased from mean of 11.15% before starting basal insulin to the mean of 8.43% within 3 to 6 month, after initiating basal insulin, this difference was significant at p < 0.001. There was no adverse effect on this medication in any of the study group. The addition of basal insulin to oral anti-diabetic medication in uncontrolled insulin-na<span style="color:#4F4F4F;font-family:"font-size:14px;white-space:normal;background-color:#F7F7F7;">ï</span>ve type 2 diabetic patients resulted in significant improvement of glycemic control, with improved HbA1c level, without adverse effects.</span> </div>展开更多
文摘We investigate whether A1C1 and A1Br are promising candidates for laser cooling. We report new ab initio calculations on the ground state X1E＋ and two low-lying states （A1H and a3H） of A1C1 and A1Br. The calculated spectroscopic constants show good agreement with available theoretical and experimental results. We also obtain the permanent dipole moments （PDMs） curve at multi-reference configuration interaction （MRCI） level of theory. The transition properties of A1H and a3H states are predicted, including the transition dipole moments （TDMs）, Franck-Condon factors （FCFs）, radiative times and radiative width. The calculated radiative lifetimes are of the order of a nanosecond, implying that they are sufficiently short for rapid laser cooling. Both A1C1 and A1Br have highly diagonally distributed FCFs which are crucial requirement for molecular laser cooling. The results demonstrate the feasibility of laser cooling A1C1 and A1Br, and we propose laser cooling schemes for A1C1 and A1Br.
文摘<div style="text-align:justify;"> <span style="font-family:Verdana;">Type 2 diabetes mellitus is a growing health problem, characterized by insulin resistance progressing to beta cell dysfunction and insulin deficiency, most of these patients will need intensification of treatment and initiation of insulin to delay or prevent diabetic complications. Glycemic control is the most important aspect of management, and in reducing morbidity and mortality of the diseases. Control of plasma glucose in patients with diabetes can be assessed by HbA1c, FPG, PPG, but still HbA1c% remains the gold standard for assessment of glycemic control and follow up of diabetic patients. The aim of this study is to assess HbA1c% in patients on oral anti-diabetic drugs, with poor glycemic control before and after adding basal insulin, with titration of the dose of insulin depending on fasting blood sugar. 82 patients with uncontrolled type 2 diabetes (43.9% male, 56.1% female), with HbA1c more than 9%, on two types of oral diabetic medication or more, were started on basal insulin (glargine, lantus) and followed for three to six months. Overall 82 patients with type 2 diabetes mellitus were included in the study. The mean age of the study population was 58.4 years, the mean duration of the disease range was 13.4 years. All patients with HbA1c more than 9%, without organ failure, were included in the study. The mean HbA1c overall had decreased from mean of 11.15% before starting basal insulin to the mean of 8.43% within 3 to 6 month, after initiating basal insulin, this difference was significant at p < 0.001. There was no adverse effect on this medication in any of the study group. The addition of basal insulin to oral anti-diabetic medication in uncontrolled insulin-na<span style="color:#4F4F4F;font-family:"font-size:14px;white-space:normal;background-color:#F7F7F7;">ï</span>ve type 2 diabetic patients resulted in significant improvement of glycemic control, with improved HbA1c level, without adverse effects.</span> </div>
